hoth therapeutics, inc., a biopharmaceutical company, focuses on developing therapies for dermatological disorders. the company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. it intends to use the biolexa platform to develop two topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures. the company has license agreements with the george washington university; the university of maryland baltimore; isoprene pharmaceuticals, inc.; the north carolina state university; chelexa biosciences, inc.; and the university of cincinnati. it also has a partnership agreement with zyl㶠therapeutics inc. co-develop a new topical treatment for patients with cutaneous lupus erythematosu, a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life. hoth therapeutics has research collaboratio
Company profile
Ticker
HOTH
Exchange
Website
CEO
Robbie Knie
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Hoth Therapeutics Australia Pty Ltd ...
IRS number
821553794
HOTH stock data
Latest filings (excl ownership)
S-1
IPO registration
11 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
424B3
Prospectus supplement
28 Mar 24
8-K
Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds
28 Mar 24
8-K
Other Events
9 Jan 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Other Events
5 Oct 23
8-K
Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
15 Sep 23
424B5
Prospectus supplement for primary offering
14 Sep 23
8-K
Submission of Matters to a Vote of Security Holders
21 Aug 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 11.83 mm | 11.83 mm | 11.83 mm | 11.83 mm | 11.83 mm | 11.83 mm |
Cash burn (monthly) | (no burn) | (no burn) | 697.66 k | 784.61 k | 545.53 k | 660.48 k |
Cash used (since last report) | n/a | n/a | 4.64 mm | 5.21 mm | 3.63 mm | 4.39 mm |
Cash remaining | n/a | n/a | 7.19 mm | 6.61 mm | 8.20 mm | 7.44 mm |
Runway (months of cash) | n/a | n/a | 10.3 | 8.4 | 15.0 | 11.3 |
Institutional ownership, Q2 2023
45.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 14 |
Opened positions | 3 |
Closed positions | 4 |
Increased positions | 3 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 216.38 mm |
Total shares | 2.24 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Iroquois Capital Management | 911.39 k | $601.00 k |
Lind Global Macro Fund | 792.29 k | $523.00 k |
IOI Ionic Ventures | 412.54 k | $272.00 k |
Intracoastal Capital | 57.01 k | $0.00 |
Geode Capital Management | 24.34 k | $73.02 mm |
Citadel Advisors | 20.43 k | $61.28 mm |
Vanguard | 12.23 k | $36.70 mm |
Integrated Wealth Concepts | 10.00 k | $30.00 mm |
UBS UBS Group AG - Registered Shares | 4.29 k | $12.88 mm |
RY Royal Bank Of Canada | 240.00 | $1.00 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
5 Jan 24 | Jeff Pavell | Options Common Stock | Grant | Acquire A | No | No | 1.36 | 25,000 | 34.00 k | 25,000 |
5 Jan 24 | Wayne Linsley | Options Common Stock | Grant | Acquire A | No | No | 1.36 | 25,000 | 34.00 k | 25,000 |
5 Jan 24 | Knie Robb | Options Common Stock | Grant | Acquire A | No | No | 1.36 | 225,000 | 306.00 k | 225,000 |
5 Jan 24 | Graig Springer | Options Common Stock | Grant | Acquire A | Yes | No | 1.36 | 100,000 | 136.00 k | 100,000 |
5 Jan 24 | Graig Springer | Options Common Stock | Grant | Acquire A | No | No | 1.36 | 25,000 | 34.00 k | 25,000 |
5 Jan 24 | Sarnoff David | Options Common Stock | Grant | Acquire A | No | No | 1.36 | 25,000 | 34.00 k | 25,000 |
News
HC Wainwright & Co. Reiterates Buy on Hoth Therapeutics, Maintains $4 Price Target
5 Apr 24
EF Hutton Maintains Buy on Hoth Therapeutics, Raises Price Target to $7
2 Apr 24
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
19 Mar 24
Why Is Alzheimer's-Focused Hoth Therapeutics Stock Trading Higher On Tuesday?
19 Mar 24
Market-Moving News for March 19th
19 Mar 24
Press releases
Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds
27 Mar 24
Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment
27 Mar 24
Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ
19 Mar 24
Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio
29 Feb 24
Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic
26 Feb 24